Panmure Gordon disclosed Maxcyte Inc (LON:MXCT), supporting its stock price target at 170.00GBX earlier today
- Updated: September 19, 2016
Panmure Gordon held the price target of Maxcyte Inc (LON:MXCT) at 170GBX, stating a possible upside of 1.01%.
On 9/06/2016, Panmure Gordon released a statement on Maxcyte Inc(LON:MXCT) bumped the target price at 170.00GBX. At the time, this suggested an upside of 1.01%.
Displaying a price of 84.50GBX, Maxcyte Inc (LON:MXCT) traded 1.78% lower on the day. The last stock price close is up 1.20% relative to the two hundred day average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. Maxcyte Inc has recorded a 50-day average of 84.50GBX and two hundred day moving average of 82.01GBX. Trade volume was was up over the average, with 965 shares of MXCT changing hands over the typical 329 shares.
Maxcyte Inc has a 52 week low of 75.00GBX and a one-year high of 86.38GBX and has a market capitalization of 0.0 GBX.
In addition to Panmure Gordon reporting it’s stock price target, a total of 1 brokerage has released a report on Maxcyte Inc. The 12-month target is 2.20GBX with 0 rating the stock a strong buy, one firm rating the company a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and lastly 0 brokeragesrating the company as sell.
About Maxcyte Inc (LON:MXCT)
MaxCyte, Inc. focuses on cell-based medicines. The Company’s cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company’s products include instruments, processing assemblies and insourcing services. Its instruments include systems, such as the MaxCyte STX, the MaxCyte VLX and the MaxCyte GT. The Company’s MaxCyte GT Flow Transfection System, the MaxCyte STX Scalable Transfection System and the MaxCyte VLX Large Scale Transfection System enable the development and production of transfected cells for an array of applications. The Company offers a platform, which enables the engineering of a range of cells, including human primary cells. Its products are used in applications, including drug discovery, protein production and cell therapy. The Company offers messenger ribonucleic acid (mRNA) CAR T-cell based platform for immuno-oncology indications, and including solid cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.